Skip to content
Screener

AbCellera Biologics Inc. ABCL Q4 2025 Annual earnings

Reported February 24, 2026 · After market close

Revenue$44.9MBeat by $38.2M
EPS-$0.03Beat by $0.15
Revenue estimate$6.7M
EPS estimate-$0.18

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$5.3M
EPS estimate-$0.18

Financials

Q4 2025

Income statement

See full
Revenue$44.9M+788%
Operating income-$28.6M+60.7%
Net income-$8.9M+73.9%
EPS (diluted)-$0.03+72.7%

Balance sheet

See full
Cash & equivalents$128.5M-17.8%
Total debt$143.2M+119%
Total equity$966.9M-8.4%
Total assets$1.4B-0.3%

Cash flow

See full
Operating cash flow-$34.7M-334%
CapEx$9.8M-37.0%
Free cash flow-$44.6M-88.7%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.02B+18.3%
Enterprise value$1.04B+34.1%
P/S13.6×-16.4×

Profitability

See full
Operating margin-289%-122pp
Net margin-194.9%-77.1pp
FCF margin-231.7%-90.6pp

Returns & leverage

See full
Return on equity-14.5%-0.3pp
Debt / equity0.1×+0.1×
Current ratio11.3×+1.5×

Segments

By product

See full
Research fees$7.7M+61.2%

FAQ

When did AbCellera Biologics Inc. report Q4 2025 earnings?
AbCellera Biologics Inc. (ABCL) reported Q4 2025 earnings on February 24, 2026 after market close.
What were AbCellera Biologics Inc.'s Q4 2025 revenue and EPS?
AbCellera Biologics Inc. reported revenue of $44.9M and eps of $-0.03 for Q4 2025.
Did AbCellera Biologics Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $6.7M by $38.2M. EPS beat the consensus estimate of $-0.18 by $0.15.
How did AbCellera Biologics Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 789.1% from $5.1M a year earlier and eps grew 72.7% from $-0.11.
Where can I find AbCellera Biologics Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001703057-26-000010) and the 10-K periodic report (0001703057-26-000012) directly on SEC EDGAR. The filing index links above go to sec.gov.